我国高发肿瘤的NCCN及CSCO治疗指南用药特征研究

Study on drug characteristics of NCCN and CSCO clinical practice guidelines for high-prevalence tumors in China

缺乏先进治疗药物和治疗药物价格高昂无法负担一直是困扰我国肿瘤患者的两大问题。为精确把握我国恶性肿瘤的临床用药特点,洞察肿瘤治疗领域的用药缺陷,更有效、更具针对性的提高临床急需抗肿瘤药品的合理使用和可获得性,本研究从临床用药种类、治疗方案特点、用药结构等方面出发对肺癌、胃癌、结直肠癌、肝癌、乳腺癌等5种高发恶性肿瘤的美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)和中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)治疗指南展开对比分析,客观描述我国抗肿瘤药物应用现状和潜在不足。提示我国抗癌药品的国内市场准入及仿制药研发有待进一步提升;肿瘤患者的联合用药方案在临床治疗、医保目录遴选、药品谈判、短缺药品监测等各方面均应加以重视;同时应积极关注尚缺乏治疗药品的癌种及单克隆抗体等前沿抗肿瘤药物的研发与生产,适当降低此类品种的进口依存度。

The lack of advanced therapeutic drugs and therapeutic drugs that are expensive and unaffordable has always been the two main problems that plague Chinese cancer patients.In order to accurately grasp the clinical drug characteristics of malignant tumors in China,identify drug defects in the field of tumor therapy,more effective and more targeted to improve the rational use and availability of clinically needed anti-tumor drugs,this study compared the National Comprehensive Cancer Network(NCCN)and Chinese Society of Clinical Oncology(CSCO)guidelines for five high-prevalence tumors including lung cancer,gastric cancer,colorectal cancer,liver cancer and breast cancer from the aspects of clinical drug types,treatment regimen characteristics and drug structures,and objectively described the current status and potential defects of anti-tumor drugs use in China.The research results showed that the domestic market access and generic drug research and development of anti-tumor drugs in China need to be further improved.And the combined drug regimen for cancer patients should be paid attention to in clinical treatment,medical insurance catalog selection,drug negotiation,and shortage drug monitoring.At the same time,we should actively pay attention to the development and production of cutting-edge anti-tumor drugs such as monoclonal antibodies and drugs for tumors lacking therapeutic drugs,and appropriately reduce the import dependence of such drug varieties.